Refine by
Blood Collection Technologies Articles & Analysis
13 news found
Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to ...
YourBio Health, formerly Seventh Sense Biosystems, Inc., developers of the world’s first push-button blood collection device, announced the launch of its website where UK consumers can order a convenient, easy to use, nearly painless and accurate COVID-19 antibody test. “We’re happy to launch our COVID-19 antibody test service to UK consumers today,” said Stephen Hahn, ...
YourBio Health, Inc., developers of the world’s first painless push-button blood collection device, announced today that Stephen Hahn, M.D. joins as interim Chief Medical Officer; he also serves as the Chief Medical Officer, for the Preemptive Medicine and Health Security initiative at Flagship Pioneering at-large. Dr. Hahn previously served as the U.S. Food and Drug Administration ...
Seventh Sense Biosystems, Inc., developers of the world’s first painless push-button blood collection device, announced today its new corporate name, YourBio Health, Inc., which reflects the company’s focus on putting health information in the hands of the individual. YourBio Health enables individuals to collect a blood sample and receive the results via a secure website from the ...
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a ...
Making blood collection simpler, more convenient, and more comfortable. That’s our mission, and we are thrilled to share that our partner, Gateway Genomics, is leveraging our TAP II blood collection technology in its product offering, the SneakPeek Early Gender DNA Test. Called SneakPeek Snap, the ...
Seventh Sense Biosystems, Inc. (7SBio), developers of the world’s first push-button blood collection device, announced today that the company has received CE mark approval from the European Commission for its TAP® II blood collection device. ...
Vascular access technology pioneer Velano Vascular today revealed that the 2021 Infusion Therapy Standards of Practice, 8th Ed., include its needle free PIVO™ device and evidence of the procedure’s improved performance for inpatient blood draws. ...
SAN FRANCISCO, January 25, 2021 — Vascular access technology pioneer Velano Vascular today revealed that the 2021 Infusion Therapy Standards of Practice, 8th Ed., include its needle free PIVO™ device and evidence of the procedure’s improved performance for inpatient blood draws. ...
Through its family of novel vascular access technologies, including the PIVO™ needle-free blood draw device, Velano has pioneered a transformative new standard of care known as One-Stick Hospitalization. This new approach to blood collection aims to reduce in-patient pain and anxiety, advance practitioner safety, and ...
Vascular access technology pioneer Velano Vascular this past week made its new streamlined remote training program widely available for hospitals around the nation. Initially developed with existing partners utilizing its PIVO™ needle-free blood draw device in the fight against COVID-19, the platform is now available for additional hospitals and systems in need of streamlined care. A ...
S. hospitals and healthcare systems are seeing significantly lower hemolysis rates in the blood specimens their staff are collecting with new technology designed for drawing blood with a single-use, sterile device that advances into the vein through a peripheral IV (PIV). The technology, PIVO (Velano Vascular, ...
San Francisco medical device company Velano Vascular closed a $25 million second round of financing, bringing its total overall to $50 million. The new capital will go toward expanding its needle-less blood draw device and to developing new technologies. CEO Eric Stone would not reveal what these new technologies will entail but said they will fall within the company’s mission ...